# A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants

> **NCT04487405** · — · TERMINATED · sponsor: **Aspira Women's Health** · enrollment: 721 (actual)

## Conditions studied

- Adnexal Mass

## Interventions

- **DEVICE:** OVAnex

## Key facts

- **NCT ID:** NCT04487405
- **Lead sponsor:** Aspira Women's Health
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-25
- **Primary completion:** 2023-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 721 (ACTUAL)
- **Why stopped:** cohort C looked at feasibility of genetics \& protein to evaluate risk with a family hx of cancer or associated variant. Since few patients show these factors, this approach would not yield sufficient information to make inferences
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04487405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04487405, "A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04487405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*